Ceranib-2 NEW
| Price | $47 | $89 | $189 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-10 |
Product Details
| Product Name: Ceranib-2 | CAS No.: 1402830-75-4 |
| Purity: 98.49% | Supply Ability: 10g |
| Release date: 2025/11/10 |
Product Introduction
Bioactivity
| Name | Ceranib-2 |
| Description | Ceranib-2 (3-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]-4-phenyl-1H-quinolin-2-one) is an inhibitor of ceramidase with an IC50 of 28 μM in SKOV3 cells. Ceranib-2 decreases levels of sphingosine and S1P, induces cell apoptosis and exhibits anticancer activity. |
| In vitro | In SKOV3 cells, Ceranib-2 (28 μM) decreases with 50% inhibition and induces the accumulation of multiple ceramide species. Ceranib-2 (10 nM-10 µM) inhibits cell proliferation and survival with an IC50 value of 0.73 μM. Ceranib-2 (0.75-1.5 µM) accumulates cells in the sub-G1. G2 and S phases of the cell cycle are concomitantly reduced in the number of cells in the G1 phase at the dose of 0.75 μM[1]. |
| In vivo | In female Balb/c mice, Ceranib-2 (20-50 mg/kg; i.p.) delays tumor growth without hematologic suppression in a syngeneic tumor model. Ceranib-2 (50 mg/kg; i.p.) increases the circulating levels, reaching a peak plasma concentration of approximately 40 μM at 2 hr[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (157.31 mM), Sonication is recommended. |
| Keywords | S1PReceptor | S1P Receptor | S1P | Ceranib-2 | Ceramidase | Apoptosis |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Metronidazole | Citric Acid Triammonium | Tributyrin | L-Methionine | Sodium citrate | Cystamine dihydrochloride | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1kg |
VIP1Y
|
Hebei Junhua Import and Export Co., LTD
|
2025-04-07 | |
| $0.00/1kg |
VIP1Y
|
Hefei Lbao Physical & Chemical Science Co.,Ltd
|
2025-11-11 | |
| $0.00/1G |
VIP1Y
|
Shenzhen Nexcon Pharmatechs Ltd.
|
2025-05-30 | |
| $47.00/5mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-11-10 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY